We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MODN
26
DELISTED
MODEL N, INC.
MODN
$15.5M 1.69%
1,461,678
+4,400
+0.3% +$44.6K
UHS icon
27
Universal Health Services
UHS
$10.1B
$15.1M 1.64%
135,270
+11,478
+9% +$1.21M
CIVI
28
DELISTED
Civitas Solutions, Inc.
CIVI
$15M 1.63%
879,485
+260,249
+42% +$4.11M
BIIB icon
29
Biogen
BIIB
$32.3B
$14.6M 1.59%
+43,113
New +$13.9M
CSLT
30
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$14.6M 1.59%
1,247,268
-436,549
-26% -$5.21M
OXFD
31
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$14.6M 1.59%
1,070,995
+4,580
+0.4% +$62.6K
GMED icon
32
Globus Medical
GMED
$11.1B
$14.5M 1.58%
611,731
-354,569
-37% -$7.85M
ARAY icon
33
Accuray
ARAY
$32.7M
$11.6M 1.26%
1,535,475
-117,653
-7% -$830K
AKAO
34
DELISTED
Achaogen Inc
AKAO
$9.58M 1.04%
733,953
-36,469
-5% -$371K
BLUE
35
DELISTED
bluebird bio
BLUE
$9.38M 1.02%
+7,892
New +$5.27M
NVRO
36
DELISTED
NEVRO CORP.
NVRO
$9.06M 0.99%
+234,254
New +$7.38M
CNXR
37
DELISTED
Connecture, Inc.
CNXR
$8.5M 0.93%
+943,000
New +$8.46M
ATRA icon
38
Atara Biotherapeutics
ATRA
$92.3M
$7.07M 0.77%
+10,571
New +$6.46M
EHTH icon
39
eHealth
EHTH
$38.4M
$6.6M 0.72%
264,942
+87,154
+49% +$2.12M
FLXN
40
DELISTED
Flexion Therapeutics, Inc.
FLXN
$6.36M 0.69%
315,144
-150,789
-32% -$2.73M
ELDN icon
41
Eledon Pharmaceuticals
ELDN
$260M
$3.17M 0.35%
1,328
-1,230
-48% -$2.92M
CARM
42
DELISTED
Carisma Therapeutics
CARM
$2.85M 0.31%
+12,000
New +$2.69M
PACB icon
43
Pacific Biosciences
PACB
$435M
$1.87M 0.2%
+237,977
New +$1.52M
LOXO
44
DELISTED
Loxo Oncology, Inc
LOXO
$1.62M 0.18%
137,681
-402,619
-75% -$4.69M
FWP
45
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$526K 0.06%
+3,605
New +$520K
CLDX icon
46
Celldex Therapeutics
CLDX
$3.07B
$476K 0.05%
+1,740
New +$433K
PPH icon
47
VanEck Pharmaceutical ETF
PPH
$993M
$418K 0.05%
6,500
– –
WCG
48
DELISTED
Wellcare Health Plans, Inc.
WCG
$401K 0.04%
4,887
-220,146
-98% -$15.3M
QQQ icon
49
Invesco QQQ Trust
QQQ
$489B
$355K 0.04%
+3,434
New +$347K
IBB icon
50
iShares Biotechnology ETF
IBB
$10.5B
$303K 0.03%
3,000
-1,956
-39% -$190K
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.